INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF
THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )
Filed by the Registrant [ ]
Filed by a Party Other than the Registrant [X]
Check the Appropriate Box:
[ ] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only (as permitted by
[ ] Definitive Proxy Statement
[X] Definitive Additional Materials
[ ] Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12
Adverum Biotechnologies, Inc.
(Name of registrant as specified in its charter)
THE SONIC FUND II, L.P.
(Name of person(s) filing proxy statement, if other than the registrant)
Payment of Filing Fee (Check the Appropriate Box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it is determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
[ ] Fee paid previously with preliminary materials:
[ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement no.:
(3) Filing Party:
(4) Date Filed:
The Sonic Fund II, L.P., together with the other participants named herein (collectively, “Sonic”), has filed with the Securities and
Exchange Commission a definitive proxy statement and an accompanying proxy card to be used to solicit votes for the election of its slate of director nominees for the Board of Directors of Adverum Biotechnologies, Inc., a Delaware corporation (the
“Issuer”) at the Issuer’s 2021 annual meeting of stockholders.
On April 26, 2021, Sonic and its affiliates issued a presentation on the Issuer, a copy of which is attached hereto
as Exhibit 99.1 (the “Presentation”). The Presentation was distributed via a press release, which is attached hereto as Exhibit 99.2, and via Sonic’s website (www.saveadverum.com), as described more fully in the definitive additional materials on
Schedule 14A to be filed with the Securities and Exchange Commission on the date hereof.
THE SONIC FUND II, L.P. ISSUES PRESENTATION CORRECTING ADVERUM’S MISSTATEMENTS
Highlights Numerous Mischaracterizations in Adverum’s Recent Investor Presentation
Sonic’s Sole Aim in this Contest is for Adverum to Have Best Board Possible to Ensure Development and Approval of
Company’s Potentially Life-Changing Treatment
Urges Stockholders to Vote on the GREEN Proxy Card Today to Elect Sonic’s Three Independent Director Nominees to
Drastically Improve Board
Honolulu, HI – April 26, 2021 – The Sonic Fund
II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or “Adverum”), today issued a supplemental presentation detailing – and correcting – a
number of the Company’s recent misstatements. Sonic has nominated three independent, highly qualified director candidates – Jean Bennett, Jodi Cook and Herbert Hughes (the “Nominees”) – for election to the Adverum Board of Directors (the “Board”)
at the 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”).
The presentation, entitled “Adverum’s Myths: Correcting the Record,” is available at: https://www.saveadverum.com/investor-materials.
Vote on the GREEN proxy card today
If you have any questions regarding your GREEN proxy card or need assistance in voting your shares, please contact
Saratoga Proxy Consulting, LLC
520 8th Avenue
New York, NY 10018
Stockholders may call toll-free: (888) 368-0379
Banks and brokers call: (212)
Saratoga Proxy Consulting LLC
John Ferguson / Ann Marie Mellone 212-257-1311
firstname.lastname@example.org / email@example.com
Sloane & Company
Joe Germani / Sarah Braunstein
firstname.lastname@example.org / email@example.com